High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer
- 7 June 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Tumor Biology
- Vol. 37 (9), 12287-12299
- https://doi.org/10.1007/s13277-016-5075-1
Abstract
Alpha-methylacyl-CoA racemase (AMACR) is a well-characterized marker extensively utilized in prostate cancer (PCA) diagnosis. However, the prognostic value of AMACR expression and its relation to TMPRSS2-ERG gene rearrangement as one of the most common molecular alterations in PCA is not fully explored. AMACR expression was investigated in a cohort of 218 men with localized PCA treated by radical prostatectomy and correlated with ERG and various clinical and pathological parameters. In vitro studies assessed AMACR changes to ERG knockdown and other related genes. In addition, bioinformatics validated the significance of AMACR/ERG expression and assessed relevant genetic signatures in relation to AMACR/ERG expression. AMACR expression was significantly associated with disease progression and with ERG (p ∼0). Seventeen percent of cancer foci showed negative/weak AMACR expression while being ERG positive. High AMACR expression was significantly associated with positive surgical margins (p = 0.01), specifically in tumors with lower Gleason score p = 0.008). High AMACR showed marginal association with PSA biochemical recurrence (BCR) (p = 0.06) which was slightly more pronounced in ERG-positive tumors (p = 0.04). This was validated in other public cohorts. However, in this cohort, the association with BCR was not statistically significant in multivariate analysis (p = 0.09). Using in vitro cellular models, AMACR messenger RNA (mRNA) expression, but not protein levels, showed an association with ERG expression. We report for the first time a significant association between AMACR and ERG with prognostic implication. Patients with high AMACR/ERG-positive PCA may be at higher risk for disease progression, and additional studies in larger cohorts are needed to confirm the above findings. Functional studies investigating the molecular pathways connecting AMACR and ERG may provide an additional insight into PCA progression pathways.Keywords
Funding Information
- Prostate Cancer Canada (B2013-01)
- Prostate Cancer Foundation
This publication has 57 references indexed in Scilit:
- TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer ModelPLOS ONE, 2011
- Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic AdenocarcinomasThe American Journal of Surgical Pathology, 2011
- ERG gene rearrangements are common in prostatic small cell carcinomasLaboratory Investigation, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationProstate Cancer and Prostatic Diseases, 2010
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerBritish Journal of Cancer, 2010
- TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomasLaboratory Investigation, 2009
- Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancerBMC Cancer, 2008
- Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancerBritish Journal of Cancer, 2007
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005